Middle East Journal of Cancer

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

News

Forms

Journal Metrics

Monoclonal Antibodies in the Treatment of Small Cell Lung Cancer: A Review of Clinical Trials

Articles in Press

Document Type : Review Article(s)

Authors

Department of Pharmacology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

10.30476/mejc.2026.109133.2355

Abstract

Small cell lung cancer (SCLC) is an aggressive type of cancer with a relatively high mortality rate after diagnosis. It has been accepted for decades that platinum-based medicines, in addition to chest radiotherapy, can be used in limited-stage of SCLC. Currently, chemotherapy or combination immunotherapy are used for treatment. However, fully successful treatment may not to be attained due to the resistance and relapse that can occur. Several reports have demonstrated that the addition of anti-programmed death-ligand 1 (anti–PD-L1) immunotherapy or cytotoxic T-cell–associated antigen antibodies and increasing of delta-like ligand 3 antigens on SCLC tumor cells into chemotherapy could improve the survival rate of patients for few years. Monoclonal Antibodies, as a new and effective class of biopharmaceutical compounds, showed broad application prospects in the treatment of SCLC. Monoclonal antibodies that specifically target cancer cells and are attached to cytotoxic drugs, allowing for targeted killing of cancer cells while healthy tissues are not affected. In this review, we discussed the therapeutic efficacy and safety of MABs in SCLC. The latest agents of this group of drugs are described. Their efficacy and challenges are discussed and compared.

Highlights

Ali Asghar Hemmati (google scholar)

 

Keywords

Main Subjects

Please cite this article as: Hemmati AS, Alaei S. Monoclonal Antibodies in the Treatment of Small Cell Lung Cancer: A Review of Clinical Trials. Middle East J Cancer. 2026: in press. doi: 10.30476/mejc.2026.109133.2355.

References
  1. Puri S, Kaur G, Piplani H, Sanyal SN, Vaish V. Imatinib modulates pro-inflammatory microenvironment with angiostatic effects in experimental lung carcinogenesis. 2020;28(1):231-52. doi: 10.1007/s10787-019-00656-8. PMID: 31676982.
  2. Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3. doi: 10.1038/s41572-020-00235-0. PMID: 33446664; PMCID: PMC8177722.
  3. Soliman M. PET/CT as a prognostic factor for small cell lung cancer. Middle East J Cancer. 2023;14(3):436-42. doi:10.30476/mejc.2022.94538.1729.
  4. Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, et al. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023;73(6):620-52. doi: 10.3322/caac.21785. PMID: 37329269.
  5. Makuku R, Khalili N, Razi S, Keshavarz-Fathi M, Rezaei N. Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy. J Immunol Res. 2021;2021:6661406. doi: 10.1155/2021/6661406. PMID: 33681388; PMCID: PMC7925068.
  6. Yang H, Yang L, Liu Y, Wang L. Adebrelimab in small cell lung cancer: From current advances to emerging combination strategy and challenge. 2025;19:365-77. doi: 10.2147/BTT.S500470. PMID: 40475251; PMCID: PMC12138384.
  7. Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739-47. doi: 10.1016/S1470-2045(22)00224-8. PMID: 35576956.
  8. Zhang F, Qi X, Wang X, Wei D, Wu J, Feng L, et al. Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. 2017;8(52):90215-24. doi: 10.18632/oncotarget.21652. PMID: 29163822; PMCID: PMC5685743.
  9. Pujol JL, Greillier L, Audigier-Valette C, Moro-Sibilot D, Uwer L, Hureaux J, et al. A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial. J Thorac Oncol. 2019;14(5):903-13. doi: 10.1016/j.jtho.2019.01.008. PMID: 30664989.
  10. Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220-9. doi: 10.1056/NEJMoa1809064. PMID: 30280641.
  11. Nishio M, Sugawara S, Atagi S, Akamatsu H, Sakai H, Okamoto I, et al. Subgroup analysis of Japanese patients in a phase III study of atezolizumab in extensive-stage small-cell lung cancer (IMpower133). Clin Lung Cancer. 2019;20(6):469-76.e1. doi: 10.1016/j.cllc.2019.07.005. PMID: 31466854.
  12. Liu SV, Mok TS, Nabet BY, Mansfield AS, De Boer R, Losonczy G, et al. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Lung Cancer. 2023;186:107418. doi: 10.1016/j.lungcan.2023.107418. PMID: 37931445.
  13. Reck M, Dziadziuszko R, Sugawara S, Kao S, Hochmair M, Huemer F, et al. Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study. Lung Cancer. 2024;196:107924. doi: 10.1016/j.lungcan.2024.107924. PMID: 39306923.
  14. Chen Z, Lu X, Koral K. The clinical application of camrelizumab on advanced hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2020;14(11):1017-24. doi: 10.1080/17474124.2020.1807939. PMID: 32762583.
  15. Zhao Y, Zhang M, Liu J, Pu H, Li Y, Li X, et al. Camrelizumab combined with chemotherapy followed by maintenance camrelizumab and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory study [abstract]. J Clin Oncol. 2024;42(16_suppl): e20107. doi: 10.1200/JCO.2024.42.16_suppl.e20107
  16. Liu M, Qiu G, Guan W, Xie X, Lin X, Xie Z, et al. Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial. Signal Transduct Target Ther. 2025;10(1):65. doi: 10.1038/s41392-025-02153-7. PMID: 39962074; PMCID: PMC11833049.
  17. Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the 'high-hanging fruit'. Nat Rev Drug Discov. 2018;17(3):197-223. doi: 10.1038/nrd.2017.227. PMID: 29192287.
  18. Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. PMID: 33285097.
  19. Park S, Noh JM, Choi Y-L, Chi SA, Kim K, Jung HA, et al. Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer. Eur J Cancer. 2022;169:42-53. doi: 10.1016/j.ejca.2022.03.034. PMID: 35500460.
  20. Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024;391(14):1313-27. doi: 10.1056/NEJMoa2404873. PMID: 39268857.
  21. Xu JX, Maher VE, Zhang L, Tang S, Sridhara R, Ibrahim A, et al. FDA approval summary: Nivolumab in advanced renal cell carcinoma after anti-angiogenic therapy and exploratory predictive biomarker analysis. 2017;22(3):311-7. doi: 10.1634/theoncologist.2016-0476. PMID: 28232599; PMCID: PMC5344649.
  22. Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆. Ann Oncol. 2021;32(5):631-41. doi: 10.1016/j.annonc.2021.01.071. PMID: 33539946.
  23. Leal TA, Wang Y, Dowlati A, Chay CH, Chen Y, Mohindra AR, et al. Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. 2025;131(12):e35938. doi: 10.1002/cncr.35938. PMID: 40526078; PMCID: PMC12276847.
  24. Poole RM. Pembrolizumab: first global approval. 2014;74(16):1973-81. doi: 10.1007/s40265-014-0314-5. PMID: 25331768.
  25. Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369-79. doi: 10.1200/JCO.20.00793. PMID: 32468956; PMCID: PMC7474472.
  26. Kim YJ, Keam B, Ock CY, Song S, Kim M, Kim SH, et al. A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer. Lung Cancer. 2019;136:122-8. doi: 10.1016/j.lungcan.2019.08.031. PMID: 31494530.
  27. Welsh JW, Heymach JV, Chen D, Verma V, Cushman TR, Hess KR, et al. Phase I trial of pembrolizumab and radiation therapy after induction chemotherapy for extensive-stage small cell lung cancer. J Thorac Oncol. 2020;15(2):266-73. doi: 10.1016/j.jtho.2019.10.001. PMID: 31605794.
  28. Ott PA, Elez E, Hiret S, Kim D-W, Morosky A, Saraf S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study. J Clin Oncol. 2017;35(34):3823-9. doi: 10.1200/JCO.2017.72.5069. PMID: 28813164.
  29. Zhang Y, Wei R, Song G, Yang X, Zhang M, Liu W, et al. Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies. 2024;16(1):2419838. doi: 10.1080/19420862.2024.2419838. PMID: 39497266; PMCID: PMC11540081.
  30. Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: The ASTRUM-005 randomized clinical trial. 2022;328(12):1223-32. doi: 10.1001/jama.2022.16464. PMID: 36166026; PMCID: PMC9516323.
  31. Lee A, Keam SJ. Tislelizumab: First approval. 2020;80(6):617-24. doi: 10.1007/s40265-020-01286-z. PMID: 32185681.
  32. Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P, et al. Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): A Multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial. J Thorac Oncol. 2024;19(7):1073-85. doi: 10.1016/j.jtho.2024.03.008. PMID: 38460751.
  33. Keam SJ. Toripalimab: First global approval. 2019;79(5):573-8. doi: 10.1007/s40265-019-01076-2. PMID: 30805896.
  34. Zhang P, Liu F, Wang D, Zheng S, Guo J, Zou Y, et al. A randomized phase II study of toripalimab consolidation or observation after concurrent chemoradiotherapy in limited-stage small cell lung cancer [abstract]. J Clin Oncol. 2024;42(16_suppl):8098. doi: 1200/JCO.2024.42.16_suppl.8098.
  35. Cheng Y, Zhang W, Wu L, Zhou C, Wang D, Xia B, et al. Toripalimab plus chemotherapy as a first-line therapy for extensive-stage small cell lung cancer: The phase 3 EXTENTORCH randomized clinical trial. JAMA Oncol. 2025;11(1):16-25. doi: 10.1001/jamaoncol.2024.5019. PMID: 39541202; PMCID: PMC11565370.
  36. Wang SD, Li HY, Li BH, Xie T, Zhu T, Sun LL, et al. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma. Int Immunopharmacol. 2016;38:81-9. doi: 10.1016/j.intimp.2016.05.016. PMID: 27258185.
  37. Wang J, Yuan R, Song W, Sun J, Liu D, Li Z. PD-1, PD-L1 (B7-H1) and tumor-site immune modulation therapy: The historical perspective. J Hematol Oncol. 2017;10(1):34. doi: 10.1186/s13045-017-0403-5. PMID: 28122590; PMCID: PMC5267378.
  38. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol. 2013;24(1):75-83. doi: 10.1093/annonc/mds213. PMID: 22858559.
  39. Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, et al. Phase III randomized trial of Ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740-8. doi: 10.1200/JCO.2016.67.6601. Erratum in: J Clin Oncol. 2019;37(34):3327. doi: 10.1200/JCO.19.02803. PMID: 27458307.
  40. Keam SJ. Tremelimumab: First approval. 2023;83(1):93-102. doi: 10.1007/s40265-022-01827-8. PMID: 36571670.
  41. Pakkala S, Higgins K, Chen Z, Sica G, Steuer C, Zhang C, et al. Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study. J Immunother Cancer. 2020;8(2):e001302. doi: 10.1136/jitc-2020-001302. PMID: 33428583; PMCID: PMC7754662.
  42. Wang H, Zheng T, Xu D, Sun C, Huang D, Liu X. Targeting DLL3: Innovative strategies for tumor treatment. 2025;17(4):520. doi: 10.3390/pharmaceutics17040520. PMID: 40284515; PMCID: PMC12030079.
  43. Johnson ML, Zvirbule Z, Laktionov K, Helland A, Cho BC, Gutierrez V, et al. Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage-SCLC: Results from the phase 3 MERU study. J Thorac Oncol. 2021;16(9):1570-81. doi: 10.1016/j.jtho.2021.03.012. PMID: 33823285.
  44. Dhillon S. Tarlatamab: First approval. 2024;84(8):995-1003. doi: 10.1007/s40265-024-02070-z. PMID: 39023700.
  45. Hummel HD, Champiat S, Olmedo Garcia ME, Boyer M, He K, Steeghs N, et al. Tarlatamab in previously treated small cell lung cancer (SCLC): DeLLphi-300 phase I study long-term outcomes and intracranial activity [abstract]. ESMO Open. 2024;9(S3). doi: 10.1016/j.esmoop.2024.102768.
  46. Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: An open-label, phase I study. J Clin Oncol. 2023;41(16):2893-903. doi: 10.1200/JCO.22.02823. PMID: 36689692; PMCID: PMC10414718.
  47. Mountzios G, Sun L, Cho BC, Demirci U, Baka S, Gümüş M, et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med. 2025;393(4):349-61. doi: 10.1056/NEJMoa2502099. PMID: 40454646.
  48. Narayanan S, Srinivas S. Incorporating VEGF-targeted therapy in advanced urothelial cancer. Ther Adv Med Oncol. 2017;9(1):33-45. doi: 10.1177/1758834016667179. PMID: 28203296; PMCID: PMC5298449.
  49. Gille H, Hülsmeyer M, Trentmann S, Matschiner G, Christian HJ, Meyer T, et al. Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class. 2016;19(1):79-94. doi: 10.1007/s10456-015-9490-5. PMID: 26650228.
  50. Spigel DR, Townley PM, Waterhouse DM, Fang L, Adiguzel I, Huang JE, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol. 2011;29(16):2215-22. doi: 10.1200/JCO.2010.29.3423. PMID: 21502556.
  51. Pujol JL, Lavole A, Quoix E, Molinier O, Souquet PJ, Barlesi F, et al. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†. Ann Oncol. 2015;26(5):908-14. doi: 10.1093/annonc/mdv065. PMID: 25688059.
  52. Syed YY. Sacituzumab Govitecan: First approval. 2020;80(10):1019-25. doi: 10.1007/s40265-020-01337-5. PMID: 32529410; PMCID: PMC7288263.
  53. Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, et al. Therapy of small cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting trop-2, sacituzumab govitecan. Clin Cancer Res. 2017;23(19):5711-9. doi: 10.1158/1078-0432.CCR-17-0933. PMID: 28679770.
  54. Dowlati A, Chiang AC, Cervantes A, Babu S, Hamilton E, Wong SF, et al. Phase 2 open-label study of sacituzumab govitecan as second-line therapy in patients with extensive-stage SCLC: Results from TROPiCS-03. J Thorac Oncol. 2025;20(6):799-808. doi: 10.1016/j.jtho.2024.12.028. PMID: 39755168.
  55. Ready NE, Ott PA, Hellmann MD, Zugazagoitia J, Hann CL, de Braud F, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: Results from the CheckMate 032 randomized cohort. J Thorac Oncol. 2020;15(3):426-35. doi: 10.1016/j.jtho.2019.10.004. PMID: 31629915.
  56. Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. J Clin Oncol. 2021;39(12):1349-59. doi: 10.1200/JCO.20.02212. PMID: 33683919; PMCID: PMC8078251.
  57. Peters S, Pujol JL, Dafni U, Dómine M, Popat S, Reck M, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Ann Oncol. 2022;33(1):67-79. doi: 10.1016/j.annonc.2021.09.011. PMID: 34562610.
  58. Malhotra J, Nikolinakos P, Leal T, Lehman J, Morgensztern D, Patel JD, et al. A phase 1-2 study of rovalpituzumab tesirine in combination with nivolumab plus or minus ipilimumab in patients with previously treated extensive-stage SCLC. J Thorac Oncol. 2021;16(9):1559-69. doi: 10.1016/j.jtho.2021.02.022. PMID: 33652156.
  59. Xie M, Vuko M, Rodriguez-Canales J, Zimmermann J, Schick M, O'Brien C, et al. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol Cancer. 2024;23(1):115. doi: 10.1186/s12943-024-02014-x. PMID: 38811992; PMCID: PMC11137956.
  60. Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: Results from the phase II TRINITY study. Clin Cancer Res. 2019;25(23):6958-66. doi: 10.1158/1078-0432.CCR-19-1133. PMID: 31506387; PMCID: PMC7105795.
  61. Udagawa H, Akamatsu H, Tanaka K, Takeda M, Kanda S, Kirita K, et al. Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. Lung Cancer. 2019;135:145-50. doi: 10.1016/j.lungcan.2019.07.025. PMID: 31446987.
  62. Zhang C, Huo Y, Shang X, Zhang T, Tang N, Wang H. Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer. Respir Res. 2024;25(1):253. doi: 10.1186/s12931-024-02885-0. PMID: 38902698; PMCID: PMC11191253.
  63. The Medicines and Healthcare products Regulatory Agency (MHRA). Tarlatamab approved to treat adult patients with small cell lung cancer. London: GOV.UK; 2024 Dec 31 [cited 2026 Jun 9]. Available from: https://www.gov.uk/government/news/tarlatamab-approved-to-treat-adult-patients-with-small-cell-lung-cancer
Middle East Journal of Cancer

Articles in Press, Accepted Manuscript
Available Online from 01 January 2027
Files
Share
How to cite
Statistics